BEAM THERAPEUTICS INC (BEAM)
Health Care · biotechnology · NASDAQ
Beam Therapeutics is a biotechnology firm pioneering base editing technology to create next-generation precision genetic medicines.
What BEAM THERAPEUTICS INC does
Beam Therapeutics is a biotechnology company focused on developing precision genetic medicines through base editing technology. The company's platform allows for precise, predictable, and efficient single-base changes within the genetic code, targeting a range of human diseases. Their pipeline includes programs for hematology, oncology, and rare genetic diseases.
Themes: genetic medicine, gene editing, precision medicine
Fundamentals
- Price$29.76 as of 2026-08-21 close
- Market cap$3.1B as of 2026-08-21
- 1-year return+85.9% 2025-08-21 close $16.01 → 2026-08-21 close $29.76
- P/En/a negative earnings
- Net margin-54.8% as of 2026-08-24
- ROE-7.7% as of 2026-08-24
- Debt / equity0.09 as of 2026-08-24
- Revenue growth (YoY)+120.0% FY2025 vs FY2024, SEC XBRL
- Revenue CAGR (3y)+31.9% SEC XBRL
- Beta2.20 as of 2026-08-24
- Last reported earnings2026-08-04 SEC EDGAR Form 8-K (Item 2.02)
How BEAM compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginbottom 25% 504 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRtop 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)bottom 10% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
BEAM is not currently in any published Top 10 list. Its scores are below.
Long-term score
Not scored for the long-term list: no shareholder return data.
Short-term score
62.5 #113 of 1,704 scored · #31 of 240 in Health Care
Volume and participation 88th: it gapped 6.9% above the previous close and has not traded back through the level it left behind — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed; setup 69th: day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 9% of the past ~6 months), which often precedes a bigger move; weakest is catalysts 50th: analysts' average price target is unchanged from the prior reading.
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
How BEAM THERAPEUTICS INC looks technically
BEAM THERAPEUTICS INC (BEAM) is trading 6.0% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 206 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 19, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 58, neither overbought (above 70) nor oversold (below 30). It just made a new 20-day high, its first since 2026-07-15, pushing above its recent trading range. It is 22.2% below its highest point of the past year. Day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 9% of the past ~6 months), which often precedes a bigger move.
Trend
8
| Distance from the 200-day | it is trading 6.0% above its 200-day average, the long-term trend line — a longer-term uptrend | +6.0% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $29.90 | $29.90 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $28.07 | $28.07 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 7 calendar days ago — the swings before that are what the structure reading is measured on | 7 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 206 trading days ago — a "golden cross", a bullish long-term signal | 206 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 6.0% above | +6.0% |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 19, below the 25 that marks a real trend) | 18.6 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 58, neither overbought (above 70) nor oversold (below 30) | 58.1 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($25.71 to $30.50) — its "stochastic" reading is 85 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 84.6 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 14 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $38.26 | $38.26 |
|---|---|---|
| From the 52-week high | it is 22.2% below its 52-week high (its highest price of the past year) | -22.2% |
| Above the 52-week low | it is 90.8% above its 52-week low (its lowest price of the past year) | +90.8% |
| Below the 52-week high | it is 22.2% below its highest point of the past year | 22.2% |
| Since a 20-day breakout | it just made a new 20-day high, its first since 2026-07-15, pushing above its recent trading range | 1 session |
| Since a 55-day breakout | it made a new 55-day low about 20 trading days ago | 20 sessions |
| All-time high | its highest closing price on record is $138.52 (set on 2021-07-02) | $138.52 |
| Given back of the 52-week move | over the past year its closes ranged ($16.01 to $37.92), and it has given back roughly a third of its rise from last year’s low — 37% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $23.68 to $24.38. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 37.2% |
| From the all-time high | it is 78.5% below its all-time high | -78.5% |
| Nearest price level | it is trading 2.0% above a support level at $29.16 — a price it turned at three times since 2025-03-07, most recently on 2026-02-13. Since 2024-08-21 it has 13 such levels below the current price and 3 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -2.0% |
| All-time low | its lowest closing price on record is $13.00 (set on 2020-03-16) | $13.00 |
| Above the all-time low | it is 128.9% above its all-time low | +128.9% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 9% of the past ~6 months), which often precedes a bigger move | 9th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.64 between its high and its low — about 5.5% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.64 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $24.77 and $29.28 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $24.77 – $27.02 – $29.28 |
| Typical daily range (% of price) | its price moves about 5.5% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.5% |
| Stretch from the 200-day average | it is trading 1.0 daily range above its 200-day average price (6.0% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.0 daily range above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.27× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 5 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 5 sessions ago |
|---|---|---|
| Since a hammer | 5 sessions ago, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | 5 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 1.2% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | +1.2% |
|---|---|---|
| Open gap | it gapped 6.9% above the previous close 2 sessions ago and has not traded back through the level it left behind at 26.57 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +6.9% |
| Gap filled | a 3.4% gap down opened on 2026-08-20 has been "filled" 1 session ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 1 session ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 6.7 percentage points (the stock gained 9.1% while the market gained 2.3%) | +6.7% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 4.5 percentage points (the stock gained 7.6% while the market gained 3.1%) | +4.5% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 3.2 percentage points (the stock gained 7.9% while the market gained 11.1%) | -3.2% |
| vs market, 12 months | over the past 12 months this stock beat the market by 65.4 percentage points (the stock gained 85.9% while the market gained 20.5%) | +65.4% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: lagging the market over 6 months, near the top of its 14-day range (overbought), trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 7.2% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 3.4% of the share price. | -7.2% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 1% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $29.41 — a volume-weighted average of daily closes over 155 sessions, not a true tick-by-tick VWAP. | +1.2% |
|---|---|---|
| Vs the average paid since it last reported | the price is 7% above the average price paid since it last reported on 2026-08-04 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $27.75 — a volume-weighted average of daily closes over 14 sessions, not a true tick-by-tick VWAP. | +7.2% |
Price levels it has turned at before
BEAM last closed at $29.76 on 2026-08-21. Since 2024-08-21 it has turned at 13 prices below its last close and 3 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $29.16 | Support | 2.0% below the last close | turned there three times · 2025-03-07 to 2026-02-13 |
| $28.51 | Support | 4.2% below the last close | turned there six times · 2024-12-02 to 2026-08-05 |
| $27.19 | Support | 8.7% below the last close | turned there three times · 2024-09-18 to 2026-04-24 |
| $32.54 | Resistance | 9.3% above the last close | turned there three times · 2024-11-11 to 2026-07-01 |
| $34.29 | Resistance | 15.2% above the last close | turned there twice · 2026-02-25 to 2026-05-11 |
| $36.66 | Resistance | 23.2% above the last close | turned there twice · 2026-01-12 to 2026-06-22 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Tested and reclaimed 200-day support · Pulled back from the 12-month high · Broke out to a new 20-day high · in a Bollinger Band volatility squeeze · trendless / choppy (low ADX) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low · bollinger bands
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.33 mean, 1=Strong Buy…5=Strong Sell) — 13 analysts
- Mean price target$52.15 range $26.00 – $80.00; median $45.00
Analyst estimates, as of 2026-08-18. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for BEAM
- Consensus EPS estimate-$1.17 next reporting period, as of 2026-08-18
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Significant and ongoing operating losses with a history of accumulated deficits.","Reliance on the successful development and regulatory approval of unproven gene editing technologies.","High dependency on strategic license and collaboration agreements for revenue generation."]
What changed in the latest 10-Q
AI-assisted comparison of BEAM's 10-Q filed 2026-05-07 against the prior one filed 2025-11-04.
Management's Discussion & Analysis (MD&A)
- Added:
- Reference to '2025 Form 10-K' for fiscal year ended December 31, 2025 in forward-looking statements disclaimer (newer filing, 2026-05-07)
- Complete 'Overview' section describing company as biotechnology platform for precision genetic medicines with base editing technology and manufacturing capabilities (newer filing, 2026-05-07)
- Complete 'Hematology' section detailing staged development strategy for sickle cell disease and beta-thalassemia treatment (newer filing, 2026-05-07)
- Complete 'Ex Vivo Base Editing via Autologous Transplant with risto-cel' subsection including BEACON trial details and clinical data from December 2025 American Society of Hematology meeting and April 2026 New England Journal of Medicine publication (newer filing, 2026-05-07)
- Specific BEACON trial results including HbF levels above 60%, HbS below 40%, editing efficiency metrics, engraftment timelines, and transfusion data (newer filing, 2026-05-07)
- Removed:
- Text is truncated in older filing at 'Risk Factors' section; no substantive removals are identifiable from the complete older text provided
- Notes:
- The older filing text appears truncated and incomplete, ending mid-sentence after 'Part I "Risk Factors Summary" and Part I'. A complete comparison cannot fully assess all removals or changes.
- The newer filing provides substantially more detailed content in the MD&A section, representing expansion rather than direct rewording of existing content.
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 8 open-market sales by insiders in the last 90 days.
- Last 30 days0 buys · 1 sell ($429037) — 1 selling insider
- Last 90 days0 buys · 8 sells ($12M) — 3 selling insiders
- Last 180 days0 buys · 13 sells ($14M) — 6 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-07-27. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about BEAM's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
6 institutional 13F filers reported holding BEAM as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 40,092,114
- Reported value $955,395,063
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 5 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
BEAM had 23,498,484 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
BEAM had 22.8% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 11.31 days to cover at the same settlement.
- Reported short interest (shares) 23,498,484
- Short interest (% of shares outstanding) 22.8%
- Prior settlement (shares) 23,215,449
- Reported change 1.22%
- Days to cover (reported) 11.31
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- CRISPR Therapeutics (CRSP)
- Editas Medicine (EDIT)
- Intellia Therapeutics (NTLA)
- Vertex Pharmaceuticals (VRTX)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare BEAM vs…
BEAM THERAPEUTICS INC is found in…
BEAM ranks in…
Frequently asked questions
What does BEAM THERAPEUTICS INC (BEAM) do?
Beam Therapeutics is a biotechnology company focused on developing precision genetic medicines through base editing technology. The company's platform allows for precise, predictable, and efficient single-base changes within the genetic code, targeting a range of human diseases. Their pipeline includes programs for hematology, oncology, and rare genetic diseases.
What sector is BEAM THERAPEUTICS INC (BEAM) in?
BEAM THERAPEUTICS INC (BEAM) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Who are BEAM THERAPEUTICS INC's (BEAM) competitors?
Notable peers of BEAM THERAPEUTICS INC (BEAM) include CRISPR Therapeutics, Editas Medicine, Intellia Therapeutics and Vertex Pharmaceuticals. This peer set is informational only — not financial advice.
Is BEAM THERAPEUTICS INC (BEAM) overbought or oversold right now?
BEAM THERAPEUTICS INC (BEAM) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 58, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on BEAM come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.